Cross-referencing clinical data
A pairing appears on this page only when a trial gave both ingredients together and measured the result. 11-keto-beta-boswellic acid has none that clears that bar.
Stitching two separate single-ingredient studies into a pairing is the one thing this engine will not do. When a study of the combination itself holds up at source, it lands here with its citation.
No invented synergy. Where actives were studied on their own rather than together, the record shows each on its own evidence, never a combined effect no trial measured.
Research strength. Research strength says how much work stands behind the combination. It is never a product score.
Independent record. Every finding is cited to a named trial, dated, and never written by the brand.
20 pairings are live across the library today. Checked 20 July 2026.
No study gave these as a pair, so they are not in the card above. But the reason they belong together is settled biochemistry, not a guess, so it is worth knowing.
Curcumin acts largely on the cyclooxygenase and NF-kB side of eicosanoid signalling while boswellic acids act on the 5-lipoxygenase arm. Blocking two branches of arachidonic acid metabolism is the stated rationale for pairing them. A randomised comparison found the combination performed better than curcumin alone on joint comfort and mobility measures in adults with age-related joint wear.
KBA is one of six boswellic acids in Boswellia serrata resin, and it is usually the marker compound the extract is standardised against. Buying the isolated acid and buying a standardised extract are different products with different accompanying chemistry. The extract carries alpha and beta boswellic acids and AKBA alongside it.
Complexing boswellic acids with phosphatidylcholine into a phytosome improves dispersion and measured plasma exposure compared with the plain extract. Delivery system work is one of the more active areas for this compound class precisely because raw bioavailability is poor. Improved exposure is a pharmacokinetic marker, not proof of a larger clinical effect.
Lecithin supplies the phospholipid needed to form a dispersible complex with a lipophilic triterpene. It is the common non-soy source used for the same purpose. The trade-off is a bulkier dose form for a given amount of active.
EPA competes with arachidonic acid as a substrate for the same enzymes, while boswellic acids inhibit 5-lipoxygenase directly. Reducing substrate and inhibiting the enzyme are complementary rather than duplicative. The combined effect on eicosanoid profile is a biochemical marker, not a demonstrated outcome.
EPA is processed by 5-lipoxygenase into the five-series leukotrienes rather than the four-series products from arachidonic acid. Combining that substrate shift with enzyme inhibition targets the same branch twice. Fish oil also supplies the lipid environment that helps a lipophilic triterpene disperse.
Gingerols show dual cyclooxygenase and lipoxygenase activity in laboratory work, which overlaps with the boswellic acid target. The two are frequently formulated together in joint comfort products for that reason. Human data on the specific combination is thin.
MSM appears alongside boswellic acids in most joint comfort formulations, acting through a different and less well characterised route. The pairing is formulation convention supported by product history rather than by combination trials. Neither compound depends on the other.
Bromelain is a proteolytic enzyme used in soft tissue comfort products and does not share a target with boswellic acids. The combination is additive by intent rather than by mechanism. Enzyme stability alongside a resin extract is a formulation consideration.
Glucosamine addresses cartilage matrix substrate supply while boswellic acids act on eicosanoid signalling. They are complementary in intent and independent in mechanism. Combination trials against each single agent are scarce.
Boswellic acids in an oil-based or softgel format sit in a matrix that can oxidise over shelf life. Tocopherol is the conventional antioxidant added to that matrix. This is a stability role rather than a physiological interaction.
Nothing specific on file for 11-keto-beta-boswellic acid. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.These are the studies our verdict leans on, chosen from the 4 we read for 11-keto-beta-boswellic acid. The full linked list is below.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.